The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | MRD to identify those who benefit the most from FLT3 inhibition with gilteritinib in CR1 of AML
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses a study (NCT02997202) investigating the efficacy of the FLT3 inhibitor gilteritinib for patients with acute myeloid leukemia (AML) who are in their first complete remission (CR1) following allogeneic stem cell transplantation (alloSCT). While the study did not show overall benefit, it successfully identified patients who benefited most from gilteritinib using measurable residual disease (MRD) assessment. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
